(2005). Access and utilization of HIV treatment and services among women sex workers in Vancouver’s Downtown Eastside. Journal of urban health
(2000). Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med
(1996). Advances in antiretroviral therapy and viral load monitoring. AIDS
(2008). al: Antiretroviral Treatment of Adult HIV Infection:
(2000). AN: Are There Gender Differences in Starting Protease Inhibitors, HAART, and Disease Progression Despite Equal Access to Care? JAIDS
(2004). Arnsten JH: Gender differences in factors associated with adherence to antiretroviral therapy.
(2000). Differential access in the receipt of antiretroviral drugs for the treatment of AIDS and its implications for survival. Arch Intern Med
(2000). et al: Access of Vulnerable Groups to Antiretroviral Therapy Among Persons in Care for HIV Disease in the United States. Health Services Research
(2002). et al: Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet
(2003). Hauck W: Relationship of Gender, Depression, and Health Care Delivery with Antiretroviral Adherence in HIV-infected Drug Users.
(2003). Hogg RS: Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. Cmaj
(2004). Hogg RS: Adherence to antiretroviral therapy and CD4 T-cell count responses among HIV-infected injection drug users. Antivir Ther (Lond)
(1998). Hogg RS: Barriers to use of free antiretroviral therapy in injection drug users. JAMA
(2000). Hogg RS: Depressive symptoms decline among persons on HIV protease inhibitors. J Acquir Immune Defic Syndr
Montaner JS: Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is
(2008). Montaner JS: Highly active antiretroviral therapy and survival in HIV-infected injection drug users. JAMA
(2009). Montaner JS: Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ
(2001). Montaner JS: Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA
(2004). Montaner JS: Staging for antiretroviral therapy among HIVinfected drug users. JAMA
Organization, Child and Adolescent Health.
(2001). RD: Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr
(2006). RD: Illicit drug use and HIV-1 disease progression: a longitudinal study in the era of highly active antiretroviral therapy.
(2007). SJ: Injection drug use and patterns of highly active antiretroviral therapy use: an analysis of ALIVE, WIHS, and MACS cohorts. AIDS research and therapy
(1988). Strathdee S: Longitudinal predictors of injection cessation and subsequent relapse among a cohort of injection drug users in
(2010). the Mortality Working Group of COHERE: Time with CD4 cell count above 500 cells/mm3 allows HIV-infected men, but not women, to reach similar mortality rates to those of the general population: a 7-year analysis.
(2003). Treatment of antiretroviral-drug-resistant HIV-1 infection. Lancet
(2001). Treisman GJ: Management of psychiatric disorders in patients infected with human immunodeficiency virus. Clin Infect Dis
(2002). Use of highly active antiretroviral therapy in a cohort of HIV-seropositive women. American journal of public health
Vermund SH: Delayed access to HIV diagnosis and care: Special concerns for the Southern United States. AIDS Care 2006, 18(Suppl 1):S35-S44.